Kadcyla wins EU marketing approval triggering milestone payment for ImmunoGen

Roche (RHHBY -0.4%) and ImmunoGen's (IMGN +1.8%) Kadcyla gets European marketing approval, triggering a $5M milestone payment to IMGN.

The drug is approved for adults with "HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received Herceptin and a taxane, separately or in combination." (PR)

The news was expected after the CHMP gave the drug a positive opinion back in September.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs